Sugi Predict

Sugi Predict / Compounds / SCHEMBL2264797

SCHEMBL2264797

SCHEMBL2264797

O=S(=O)(Cl)c1ccc2c(c1)Cc1cc(S(=O)(=O)Cl)ccc1-2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.58
▸ MEN1 O00255 5/20 0.58
▸ CASP6 P55212 1/20 0.58
▸ GFER P55789 1/20 0.58
▸ GAA P10253 2/20 0.47
▸ PKM P14618 1/20 0.47
▸ MAPT P10636 8/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ LMNA P02545 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ RAB9A P51151 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ DUSP5 Q16690 1/20 0.39
▸ DUSP6 Q16828 1/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ HPGD P15428 3/20 0.39
▸ USP2 O75604 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6162025 0.91 KDM4E (0.54) KMT2AMEN1CASP6GFERGAA
SCHEMBL9780205 0.89 KMT2A (0.49) KMT2AMEN1CASP6GFERGAA
SCHEMBL9786190 0.78 KMT2A (0.58) KMT2AMEN1CASP6GFERGAA
SCHEMBL29902411 0.78 MEN1 (0.63) KMT2AMEN1CASP6GFERGAA
Potassium Ion SCHEMBL2956793 0.78 KMT2A (0.58) KMT2AMEN1CASP6GFERGAA
SCHEMBL9786187 0.78 DUSP5 (0.59) KMT2AMEN1CASP6GFERGAA
SCHEMBL2951392 0.78 KMT2A (0.58) KMT2AMEN1CASP6GFERGAA
SCHEMBL7194507 0.78 BCHE (0.39) KMT2AMEN1CASP6GFERGAA
SCHEMBL2330175 0.77 CA12 (0.60) KMT2AMEN1PKMKDM4ELMNA
Potassium SCHEMBL2956797 0.77 KMT2A (0.56) KMT2AMEN1CASP6GFERGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11932599-B2 Ferroptosis inducing compound, compositions comprising the same, and methods of inducing ferroptosis UNIVERSITY OF MASSACHUSETTS (US) 2024-03-19 — — US disclosed
US-20220324798-A1 FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSIS UNIVERSITY OF MASSACHUSETTS 2022-10-13 — — US disclosed
US-20130243698-A1 RADICAL POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-09-19 — — US disclosed
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 — — US disclosed
EP-2539333-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-01-02 — — EP disclosed
WO-2011104266-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-09-01 — — WO disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 — — US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-7595144-B2 Sulfonate-containing anti-reflective coating forming composition for lithography NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-09-29 — — US disclosed
US-20070134729-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2007-06-14 — — US disclosed
US-20070134729-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2007-06-14 — — US disclosed
US-7217738-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-15 — — US disclosed
US-7217738-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-15 — — US disclosed
US-7211695-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-01 — — US disclosed
US-7211695-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-01 — — US disclosed
US-7179794-B2 Multivalent macrolide antibiotics THERAVANCE, INC. (US) 2007-02-20 — — US disclosed
US-7179794-B2 Multivalent macrolide antibiotics THERAVANCE, INC. (US) 2007-02-20 — — US disclosed
US-7173039-B2 Protein kinase inhibitors THERAVANCE, INC. (US) 2007-02-06 — — US disclosed
US-7173039-B2 Protein kinase inhibitors THERAVANCE, INC. (US) 2007-02-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932599-B2 Ferroptosis inducing compound, compositions comprising the same, and methods of inducing ferroptosis AIFM2, AIFM1, FECH KMT2A 3342/4885MEN1 1324/4885CASP6 132/4885
US-20070134729-A1 Novel antibacterial agents ENGASE, PGLS, PEPD KMT2A 3543/4885MEN1 3984/4885CASP6 2287/4885
US-20130243698-A1 RADICAL POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION MT-ND4, NME4, PRDX5 KMT2A 4381/4885MEN1 1352/4885CASP6 2872/4885
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 KMT2A 3756/4885MEN1 863/4885CASP6 23/4885
US-20090306134-A1 Muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 KMT2A 1220/4885MEN1 3774/4885CASP6 4876/4885
US-20220324798-A1 FERROPTOSIS INDUCING COMPOUND, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF INDUCING FERROPTOSIS AIFM2, AIFM1, FECH KMT2A 3342/4885MEN1 1324/4885CASP6 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.